Close

Mimetica

What

Drug development

CEO

Michael Thurn

Mimetica is a Brisbane-based biotechnology company which has developed a proprietary class of small molecule scaffolds that mimic reverse-turn motifs of peptides. These scaffolds have been used to create novel small molecule mimics of several important peptides and proteins known to be involved in the pathogenesis of disease. Mimetica is currently focusing its initial drug development activities on dermatological applications.